VolitionRx Limited (VNRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 382.70%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 38.21%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 382.70% | Research and development expense / revenue. Period ending 2026-06-30. $9.41M ÷ $2.46M × 100 ≈ 382.70% |
| Stock-based compensation / revenue · 12 months | 38.21% | Share-based compensation / revenue. Period ending 2026-06-30. $939.28K ÷ $2.46M × 100 ≈ 38.21% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.41M USD | Research and Development Expense |
| Revenue | 2.46M USD | |
| Stock-based compensation | 939.28K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -19.45M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.41M | $2.46M | $939.28K | $-19.45M | (m) | 382.70% | 38.21% | (m) | (m) |
| 2026-03-31 | $10.33M | $2.47M | $1.51M | $-21.57M | (m) | 418.73% | 61.37% | (m) | (m) |
| 2025-12-31 | $10.08M | $1.73M | $1.74M | $-21.74M | (m) | 583.62% | 100.71% | (m) | (m) |
| 2025-09-30 | $10.20M | $1.47M | $2.20M | $-22.70M | (m) | 692.97% | 149.34% | (m) | (m) |
| 2025-06-30 | $11.39M | $1.32M | $1.91M | $-23.47M | (m) | 863.25% | 144.98% | (m) | (m) |
| 2025-03-31 | $12.38M | $1.31M | $1.31M | $-24.16M | (m) | 946.56% | 100.03% | (m) | (m) |
| 2024-12-31 | $14.41M | $1.23M | $1.27M | $-27.02M | (m) | 1167.93% | 102.84% | (m) | (m) |
| 2024-09-30 | $16.36M | $1.29M | $1.41M | $-29.98M | (m) | 1272.57% | 109.54% | (m) | (m) |
| 2024-06-30 | $17.54M | $976.52K | $1.62M | $-32.77M | (m) | 1796.17% | 166.20% | (m) | (m) |
| 2024-03-31 | $19.28M | $797.03K | $2.01M | $-35.33M | (m) | 2418.40% | 251.82% | (m) | (m) |
| 2023-12-31 | $19.55M | $775.30K | $2.29M | $-35.99M | (m) | 2521.79% | 295.31% | (m) | (m) |
| 2023-09-30 | $18.38M | $651.04K | $-584.60K | $-35.26M | (m) | 2822.74% | -89.79% | (m) | (m) |
| 2023-06-30 | $18.06M | $518.55K | $-483.50K | $-34.60M | (m) | 3482.83% | -93.24% | (m) | (m) |
| 2023-03-31 | $15.89M | $341.99K | $-221.37K | $-33.15M | (m) | 4645.81% | -64.73% | (m) | (m) |
| 2022-12-31 | $14.57M | $306.39K | $0.00 | $-31.78M | (m) | 4756.17% | 0.00% | (m) | (m) |
| 2022-09-30 | $16.43M | $200.92K | (m) | $-32.55M | (m) | 8175.33% | (m) | (m) | (m) |
| 2022-06-30 | $14.89M | $193.69K | (m) | $-32.12M | (m) | 7687.04% | (m) | (m) | (m) |
| 2022-03-31 | $15.26M | $178.72K | (m) | $-29.92M | $154.65K | 8538.05% | (m) | -193.50× | Reported |
| 2021-12-31 | $15.54M | $90.03K | $2.45M | $-28.33M | $155.80K | 17262.05% | 2721.55% | -181.85× | Reported |
| 2021-09-30 | $15.93M | $82.92K | (m) | $-25.21M | $159.33K | 19217.63% | (m) | -158.21× | Reported |
| 2021-06-30 | $14.67M | $58.01K | (m) | $-22.15M | $155.28K | 25287.63% | (m) | -142.64× | Reported |
| 2021-03-31 | $14.51M | $38.42K | (m) | $-21.46M | $138.20K | 37772.91% | (m) | -155.29× | Reported |
| 2020-12-31 | $14.53M | $13.43K | (m) | $-21.25M | $129.80K | 108195.21% | (m) | -163.70× | Reported |
| 2020-09-30 | $13.34M | $6.31K | $1.35M | $-19.31M | $-130.97K | 211233.07% | 21382.99% | (m) | Reported |
| 2020-06-30 | $12.80M | $22.83K | $1.29M | $-18.99M | $-133.41K | 56046.14% | 5658.01% | (m) | Reported |
| 2020-03-31 | $11.78M | (m) | $1.29M | $-17.93M | $-130.25K | (m) | (m) | (m) | Reported |
| 2019-12-31 | $10.36M | $17.10K | $1.46M | $-16.04M | $-126.57K | 60618.00% | 8531.86% | (m) | Reported |
| 2019-09-30 | $10.66M | (m) | $1.78M | $-16.57M | $94.06K | (m) | (m) | -176.19× | Reported |
| 2019-06-30 | $10.75M | (m) | $1.90M | $-16.80M | $124.60K | (m) | (m) | -134.86× | Reported |
| 2019-03-31 | $10.96M | (m) | $2.01M | $-17.24M | $118.04K | (m) | (m) | -146.09× | Reported |
| 2018-12-31 | $10.91M | (m) | $2.57M | $-17.90M | $110.92K | (m) | (m) | -161.35× | Reported |
| 2018-09-30 | $11.13M | (m) | $2.48M | $-18.03M | $101.52K | (m) | (m) | -177.62× | Reported |
| 2018-06-30 | $10.53M | (m) | $2.60M | $-17.46M | $90.03K | (m) | (m) | -193.93× | Reported |
| 2018-03-31 | $9.66M | (m) | $2.75M | $-16.34M | $83.91K | (m) | (m) | -194.70× | Reported |
| 2017-12-31 | $8.91M | (m) | $2.44M | $-15.05M | $73.13K | (m) | (m) | -205.73× | Reported |
| 2017-09-30 | $7.43M | (m) | $2.40M | $-14.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $7.20M | (m) | $2.32M | $-13.61M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $7.22M | (m) | $2.11M | $-13.12M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $6.84M | (m) | $1.68M | $-12.27M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $6.92M | (m) | $1.62M | $-11.62M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $6.79M | (m) | $1.64M | $-11.11M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $6.35M | (m) | $1.35M | $-10.15M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $6.10M | (m) | $1.49M | $-10.01M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $5.74M | (m) | $1.44M | $-9.22M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $4.95M | (m) | $1.11M | $-8.02M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $4.38M | (m) | $1.02M | $-7.05M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $4.04M | $14.79K | $767.48K | $-5.94M | (m) | 27352.20% | 5190.96% | (m) | (m) |
| 2014-09-30 | $3.48M | (m) | $356.95K | $-5.75M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $2.93M | (m) | $200.42K | $-4.91M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $2.78M | (m) | $243.71K | $-4.91M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $2.50M | (m) | $282.01K | $-4.58M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $2.90M | (m) | $650.24K | $-4.36M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $3.01M | (m) | $683.61K | $-4.31M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $2.92M | (m) | $735.34K | $-4.19M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $2.84M | $54.97K | $858.41K | $-4.08M | (m) | 5171.34% | 1561.66% | (m) | (m) |
| 2012-09-30 | $2.33M | $54.97K | (m) | (m) | (m) | 4244.84% | (m) | (m) | (m) |
| 2012-06-30 | $1.96M | $27.38K | (m) | (m) | (m) | 7164.71% | (m) | (m) | (m) |
| 2012-03-31 | $1.81M | $15.67K | (m) | (m) | (m) | 11571.31% | (m) | (m) | (m) |
| 2011-12-31 | $1.51M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |